225 genes (e.g. CYP2D6, 2C9, 2C19) that directly effect drug metabolism represents with 1,936 relevant pharmacogenetic markers by Affymetrix DMET PLUS arrays which enables detailed genetic variation analysis.

Variations that cannot be detected by old fashioned SNP analysis can be detected with this special technique. By using both rare and common SNPs allows all variant classes to be genotyped. Detect all insertions, deletions and single nucleotide polymorphisms in the gene.

These 1,936 pharmacogenetic markers, which are relevant to the genes that effect drug metabolism and designed into the array, are specially selected from the researches in the literature. Affymetrix DMET PLUS arrays which is prefered especially in the area of cardiology, oncology and psychiatry for personalized medicine and dosage application can be used in the clinical trials for finding new markers, discovering chemotherapeutic agents and studying drug effects.

Due to shorter hands-on time, genotype-specific active ingredient selection and/or right dosage arrangement features of Affymetrix DMET PLUS arrays, it is reviewed favorably by FDA (Food and Drug Administration) in USA, EMEA (European Medicines Agency) in Europe.